REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

February 7, 2024

https://www.prnewswire.com/news-releases/regenxbio-announces-completion-of-enrollment-in-cohort-2-and-additional-positive-interim-data-in-affinity-duchenne-trial-302055713.html

ROCKVILLE, Md., Feb. 7, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that enrollment has completed at dose level 2 and reported additional interim safety and efficacy in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 4 to11 years old.

Read more at prnewswire.com

Related news for (RGNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.